SMO ClinPlus CO.,LTD. (SHE:301257)
33.77
+1.05 (3.21%)
Oct 30, 2026, 4:00 PM EST
SMO ClinPlus CO.,LTD. Revenue
SMO ClinPlus CO.,LTD. had revenue of 213.85M CNY in the quarter ending September 30, 2026, a decrease of -2.31%. This brings the company's total for the last twelve months to 819.71M, up 0.08% year-over-year. In the year 2025, SMO ClinPlus CO.,LTD. had annual revenue of 842.50M with 4.82% growth. That makes SMO ClinPlus CO.,LTD. the 21,125th largest company in the world by revenue and 3,883rd in China.
Revenue (ttm)
819.71M
Revenue Growth
+0.08%
P/S Ratio
3.25
Revenue / Employee
178.31K
Employees
4,597
Market Cap
2.67B
Revenue by Geography
- China 802.81M 99.9%
- Overseas 922.00K 0.1%
Fiscal year ended Dec 31, 2024 See the full SMO ClinPlus CO.,LTD. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 842.50M | 38.78M | 4.82% |
| Dec 31, 2024 | 803.73M | 43.69M | 5.75% |
| Dec 31, 2023 | 760.04M | 173.81M | 29.65% |
| Jan 1, 2023 | 586.23M | 83.27M | 16.55% |
| Dec 31, 2021 | 502.97M | 167.68M | 50.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Runda Medical Technology | 6.52B |
| Maccura Biotechnology Co.Ltd | 2.18B |
| Medicalsystem Biotechnology | 1.68B |
| Shanghai Labway Clinical Laboratory | 1.28B |
| Amoy Diagnostics | 1.20B |
| Berry Genomics Co.,Ltd | 920.76M |
| Thalys Medical Technology Group | 709.31M |
| Guangdong Hybribio Biotech | 641.66M |